Skip to main content

Table 3 Safety and efficacy analysis of HIV and HBV/HCV cohorts

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Cohorts (N)ORRa
N (%)
Any Grade irAEs
N (%)
Grade ≥ 3 irAEs
N (%)
HIV (21)2 CR/3 PR (28)5 (24)3 (14)
HBV/HCV (34)6 PR (18)15 (44)10 (29)b
  1. aResponse evaluable patients HIV: 18; HBV/HCV: 34, b Two patients with baseline grade ≥ 2 hepatitis